KLINIKUM DER UNIVERSITAET REGENSBURG

Their core work

University Hospital Regensburg is a major German academic medical center that combines clinical care with translational research, particularly in immunology, transplantation medicine, and kidney disease. Their research focuses on understanding immune regulation — how the body's defenses can be tuned to accept transplanted organs, fight cancer, or manage chronic conditions like diabetes-related kidney damage. They bring strong clinical trial infrastructure and biobanking capabilities, bridging the gap between laboratory immunology discoveries and patient-facing treatments. Their work spans from personalized medicine biomarkers to advanced cell-based therapies for organ transplant patients.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), Regensburg concentrated on classical clinical research themes: diabetic kidney disease biomarkers, immune regulation in transplantation, and cancer immunotherapy networks. From 2019 onward, their focus broadened into advanced therapeutic products — cell-based therapies (INsTRuCT), nanovaccines for cancer (PAVE), and tissue engineering for musculoskeletal repair (MEFISTO, Achilles). There is a clear shift from understanding disease mechanisms toward developing and testing next-generation treatments, including ATMPs and personalized nanomedicine.

Regensburg is moving from diagnostic biomarker research toward therapeutic development — particularly cell-based and personalized therapies for transplantation and cancer — making them an increasingly relevant partner for clinical-stage ATMP projects.

How they like to work

Regensburg operates as both a project leader and an experienced consortium partner, coordinating 4 of their 13 projects (31%), which is above average for a clinical institution. They work across 166 unique partners in 27 countries, indicating a broad European network rather than dependence on a few repeat collaborators. Their participation in both large RIA consortia and focused MSCA training networks suggests they are comfortable in diverse project formats and can contribute clinical expertise, patient cohorts, and training infrastructure.

With 166 unique consortium partners across 27 countries, Regensburg maintains one of the broader collaboration networks among German university hospitals. Their reach is pan-European with no obvious geographic concentration, reflecting the international nature of clinical research and training networks.

What sets them apart

Regensburg stands out for its dual strength in transplantation immunology and tinnitus research — an unusual combination that reflects deep, specialist teams rather than generic participation. As a coordinator of both the European tinnitus training school (ESIT) and the tinnitus treatment unification project (UNITI), they are arguably Europe's leading academic center for tinnitus in the H2020 landscape. For transplantation and ATMP partners, they offer the rare combination of immunology expertise, clinical trial infrastructure, and regulatory experience with advanced therapy medicinal products.

Highlights from their portfolio

• REGiREG
  Largest single grant (EUR 1.5M) and an ERC Consolidator Grant — a mark of individual scientific excellence in adaptive immune regulation.
• UNITI
  Coordinated a EUR 884K effort to unify tinnitus treatments with personalized medicine approaches, building on their earlier ESIT training network — showing strategic long-term investment in this field.
• TREGeneration
  EUR 1.4M contribution to address chronic graft-versus-host disease after stem cell transplantation, demonstrating their strength in translational transplant immunology.